Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albin, R. L.
Right arrow Articles by Frey, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albin, R. L.
Right arrow Articles by Frey, K. A.
Related Collections
Right arrow All Movement Disorders
Right arrow Parkinson's disease/Parkinsonism

Neurology 2003;60:390-394
© 2003 American Academy of Neurology
Views & Reviews

Initial agonist treatment of Parkinson disease

A critique

Roger L. Albin, MD and Kirk A. Frey, MD PhD

From the Departments of Neurology (Drs. Albin and Frey) and Radiology (Nuclear Medicine) (Dr. Frey); and Geriatric Research, Education, and Clinical Center (Dr. Albin), Ann Arbor VAMC, University of Michigan, Ann Arbor.

Address correspondence and reprint requests to Dr. Roger L. Albin, 4412D, Kresge III Building, 200 Zina Pitcher Place, Ann Arbor, MI, 48109-0585; e-mail: ralbin{at}umich.edu

The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. E. Ahlskog
Beating a dead horse: Dopamine and Parkinson disease
Neurology, October 23, 2007; 69(17): 1701 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Palhagen, E. Heinonen, J. Hagglund, T. Kaugesaar, O. Maki-Ikola, R. Palm, and the Swedish Parkinson Study Group
Selegiline slows the progression of the symptoms of Parkinson disease
Neurology, April 25, 2006; 66(8): 1200 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Kurlan
"Levodopa phobia": A new iatrogenic cause of disability in Parkinson disease
Neurology, March 8, 2005; 64(5): 923 - 924.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
Parkinson Study Group
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations: The PRESTO Study
Arch Neurol, February 1, 2005; 62(2): 241 - 248.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Ravina, D. Eidelberg, J. E. Ahlskog, R. L. Albin, D. J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, et al.
The role of radiotracer imaging in Parkinson disease
Neurology, January 25, 2005; 64(2): 208 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. J. Weiner
Initial Treatment of Parkinson Disease: Levodopa or Dopamine Agonists
Arch Neurol, December 1, 2004; 61(12): 1966 - 1969.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
M. B. Stern
Dopamine Agonists Modify the Course of Parkinson Disease
Arch Neurol, December 1, 2004; 61(12): 1969 - 1971.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
E. S. Roach
Initial Parkinson Disease Therapy: Levodopa, Dopamine Agonists, or Both?
Arch Neurol, December 1, 2004; 61(12): 1972 - 1973.
[Full Text] [PDF]

Home page
 JNMHome page
J. Schwarz, A. Storch, W. Koch, O. Pogarell, P. E. Radau, and K. Tatsch
Loss of Dopamine Transporter Binding in Parkinson's Disease Follows a Single Exponential Rather Than Linear Decline
J. Nucl. Med., October 1, 2004; 45(10): 1694 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. B. Montgomery, T. Pan, W. Le, J. Jankovic, J. E. Ahlskog, G. F. Wooten, R. L. Albin, and K. A. Frey
Slowing Parkinson's disease progression: Recent dopamine agonist trials
Neurology, January 27, 2004; 62(2): 343 - 345.
[Full Text] [PDF]

Home page
 JAMAHome page
A. H. V. Schapira and C. W. Olanow
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
JAMA, January 21, 2004; 291(3): 358 - 364.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. G. Standaert
Introduction: Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease
Neurology, December 9, 2003; 61(90116): S30 - 31.
[Full Text]

Home page
 Arch NeurolHome page
C. W. Shults
Treatments of Parkinson Disease: Circa 2003
Arch Neurol, December 1, 2003; 60(12): 1680 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. B. Montgomery Jr., G. F. Wooten, J. E. Ahlskog, R. L. Albin, and K. A. Frey
Agonists versus levodopa in PD: The thrilla of whitha
Neurology, November 25, 2003; 61(10): 1462 - 1463.
[Full Text] [PDF]

Home page
 NeurologyHome page
G.F. Wooten
Agonists vs levodopa in PD: The thrilla of whitha
Neurology, February 11, 2003; 60(3): 360 - 362.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Initial agonist treatment of Parkinson disease: A critique
Erwin B Montgomery
Neurology Online, 19 Jun 2003 [Full text]
Reply to Letter to the Editor
Roger L Albin, et al.
Neurology Online, 19 Jun 2003 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.